Meanwhile, figures from 2023 show that slightly more than half (57%) of the GLP-1 diabetes drugs in the market are Semaglutide
T., Rubino, D
Common Injection Mistakes & How to Avoid Them Reusing Needles: Always use a new needle for each injection
Recommendations- To take advantage of the opportunities, The Business Research Company recommends the GLP-1 receptor agonist companies to focus on expanding oral and patient-centric GLP-1 therapies, focus on advancing dual GLP-1/GIP therapies for superior obesity outcomes, focus on developing dual GLP-1/glucagon agonists for metabolic liver disease, focus on expanding semaglutide and tirzepatide offerings to capture high-growth segments, focus on expanding oral glp-1 therapies to capture rapidly growing market demand, focus on wind power systems as the fastest-growing segment, focus on variable speed drives to capture high-growth opportunities, focus on expanding distribution channels across non-traditional care settings, focus on strategic pricing to enhance market access and competitiveness, focus on educating healthcare providers to drive adoption, focus on patient-centric awareness campaigns to expand engagement, focus on expanding GLP-1 access through other users channels.
MyStart Health is a direct-access GLP-1 provider
If research continues to show GLP-1 drugs can significantly reduce cancer risk, these medications could become a new tool in cancer prevention strategies
